TY - JOUR T1 - Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes JF - Evidence Based Medicine JO - Evid Based Med SP - 28 LP - 28 DO - 10.1136/ebmed-2016-110566 VL - 22 IS - 1 AU - Sheila A Doggrell Y1 - 2017/03/01 UR - http://ebm.bmj.com/content/22/1/28.abstract N2 - Commentary on: Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311–22OpenUrlCrossRefPubMed.Despite the treatments available for type 2 diabetes, about two-thirds of these patients die from associated heart disease or stroke.1 Approval of the first glucagon-like peptide-1 agonist (GLP-1), exenatide, by the FDA in 2005 generated an expectation that the clinical outcomes in type 2 diabetes would be improved. However, we still do not have definitive evidence that exenatide does this, although a clinical trial to determine this, the Exenatide Study of Cardiovascular Even Lowering (EXSCEL) trial, is under way.2 Subsequently, other GLP-1 receptor agonists, including liraglutide, have also been approved and used for 10 years without clinical outcome data.3 Recently, the results of Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcomes … ER -